Japan approves Bristol-Myers' nivolumab, hep C combo; CMS tweaks Sunshine Act;

> Bristol-Myers Squibb's ($BMS) Opdivo (nivolumab), an immuno-oncology drug for advanced melanoma, has scored its first regulatory green light, grabbing Japanese approval. Release

> Japan has approved Bristol-Myers Squibb's ($BMS) next-gen hepatitis C cocktail, made up of Daklinza and Sunvepra. Release

> The Centers for Medicare & Medicaid Services (CMS) announced plans to enact changes to the Open Payments program, including the Sunshine exemption for continuing medical education. More

> AstraZeneca ($AZN) will hold a Twitter chat to answer questions about its home-delivery program. Blog

> Celgene's ($CELG) Imnovid, a multiple myeloma drug, was rejected by the Scottish Medicines Consortium despite the recognition of its ability to significantly improve chances of survival. Sanofi's ($SNY) Lemtrada and Roche's ($RHHBY) MabThera both received positive recommendations. Story

> Takeda Pharmaceutical is taking heat for publishing a 74-page report on a probe of a "misleading" ad for its Blopress high blood pressure medicine--exclusively in Japanese. More (sub. req.)

And Finally... Taiwan's Gala Television has been fined $200,000 for using the name of a Taiwanese pharmaceutical company as a title sponsor for a singing contest. News

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?